Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gamma-irradiated amniotic membrane is a biological tissue graft derived from the human placenta, specifically the innermost layer of the fetal membranes. For therapeutic use, the tissue undergoes a preservation and sterilization process that involves decellularization, lyophilization (freeze-drying), and terminal sterilization using gamma radiation (typically at a dose of 25 kGy). This process ensures the material is sterile and shelf-stable for up to five years while maintaining the integrity of the extracellular matrix. It acts as a biological scaffold rich in collagen, fibronectin, and laminin, facilitating tissue regeneration, reducing inflammation, and providing structural support. In gynecological surgery, it is used as an alternative to synthetic mesh in procedures like posterior colporrhaphy to repair pelvic organ prolapse defects, such as rectoceles, by reinforcing the rectovaginal fascia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gamma-irradiated amniotic membrane.